Lenvatinib, an inhibitor of VEGFRs, was also evaluated for the treatment plan for its ability to address both angiogenesis and the possible VEGF pathway activation due to the TP53 alteration and because of its efficacy reported on AML cell lines (19). Here, TP53 is linked to acute myeloid leukemia.